Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715770 | 1.00 | AAK1 (0.42) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| Water SCHEMBL29947214 | 0.98 | AAK1 (0.41) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| Water SCHEMBL29902298 | 0.98 | AAK1 (0.41) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| SCHEMBL29760421 | 0.92 | SMN1; SMN2 (0.41) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| SCHEMBL16026595 | 0.84 | MEN1 (0.37) | KDM4EALDH1A1KMT2ALMNARAB9A | |
| SCHEMBL4632498 | 0.80 | AAK1 (0.39) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| SCHEMBL12979662 | 0.80 | SMN1; SMN2 (0.46) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| SCHEMBL19316681 | 0.80 | SMN1; SMN2 (0.46) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| SCHEMBL8902371 | 0.80 | SMN1; SMN2 (0.42) | AAK1KDM4ESMN1; SMN2PKMALDH1A1 | |
| SCHEMBL3714585 | 0.80 | ALDH1A1 (0.50) | AAK1SMN1; SMN2PKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051309-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | claimed |
| CN-115335359-A | Ocular targeting compounds and their use in treating ocular diseases | 比奥菲蒂斯公司 | 2022-11-11 | — | — | CN | claimed |
| EP-4077316-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115087655-A | Benzimidazole derivatives | 辉瑞公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114901665-A | Use of triazolotriazine derivatives for the treatment of diseases | 浙江春禾医药科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2022013307-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-01-20 | — | — | WO | claimed |
| EP-2958910-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | Domainex Limited (GB) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128486-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2014-08-28 | — | — | WO | claimed |
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | claimed |
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1287001-B1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | claimed |
| CN-114901665-B | Use of triazolotriazine derivatives in the treatment of diseases | 浙江春禾医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-107417644-B | Preparation method of acrylamide compound | 深圳有为技术控股集团有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-115335359-A | Ocular targeting compounds and their use in treating ocular diseases | 比奥菲蒂斯公司 | 2022-11-11 | — | — | CN | disclosed |
| US-4658031-A | Synthesis of 2-substituted-5-methyl-pyridines and intermediates therefor | ICI AMERICAS INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4584380-A | Synthesis of 2-substituted-5-methyl-pyridines and intermediates therefor | ICI AMERICAS INC. (US) | 1986-04-22 | — | — | US | disclosed |
| US-4473696-A | Synthesis of 2-substituted-5-methyl-pyridines | ICI AMERICAS INC. (US) | 1984-09-25 | — | — | US | disclosed |
| EP-0108483-A2 | Synthesis of 2-substituted-5-methyl-pyridines and intermediates therefor | ICI AMERICAS INC. (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | ITK, PDXK, HRH4 | AAK1 457/4885KDM4E 1701/4885SMN1; SMN2 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.